BN ImmunoTherapeutics, Inc. (Mountain View, CA), has initiated Phase 1/2 clinical studies with its therapeutic vaccine candidate against prostate cancer.
BN ImmunoTherapeutics, Inc. (Mountain View, CA), has initiated Phase 1/2 clinical studies with its therapeutic vaccine candidate against prostate cancer.
A Phase 1/2 safety and tolerability study in 18 male patients with nonmetastatic as well as hormone-insensitive prostate cancer has begun enrollment in the US. Secondary objectives of the trial include examining the ability of the vaccine to induce prostate antigen-specific immune responses, as well as clinical anti-tumor activity. Preliminary data is expected during the second half of 2009.
The therapeutic vaccine, based on the company's MVA-BN(R) technology, is designed to generate cellular and humoral immune responses to prostate specific antigen (PSA) and prostatic acid phosphatase (PAP), which are both well-known prostate cancer tumor targets.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.